Rituximab and Pegylated Interferon α-2b in Patients With Indolent B-cell Lymphoma
Status:
Recruiting
Trial end date:
2023-01-16
Target enrollment:
Participant gender:
Summary
A phase 2 open label study to evaluate safety and activity of Rituximab(HLX01) in combination
with Pegylated interferon α-2b in patients with newly diagnosed advanced indolent B-cell
lymphoma.